LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Home・Akciju saraksts・Vivani Medical

Vivani Medical

Slēgts

1.16

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.16

Max

1.2

Galvenie mērījumi
By Trading Economics
Darbinieki	37

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+241.88% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 30. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-16M 88M
Iepriekšējā atvēršanas cena	1.16
Iepriekšējā slēgšanas cena	1.16

Vivani Medical Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 13. febr. 16:32 UTC

Peļņas

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

2026. g. 13. febr. 21:57 UTC

Peļņas

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

2026. g. 13. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 13. febr. 21:20 UTC

Peļņas

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

2026. g. 13. febr. 21:05 UTC

Iegādes, apvienošanās, pārņemšana

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

2026. g. 13. febr. 20:45 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 13. febr. 20:45 UTC

Tirgus saruna

Dollar Pares Down Early Losses -- Market Talk

2026. g. 13. febr. 20:39 UTC

Tirgus saruna

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

2026. g. 13. febr. 20:28 UTC

Tirgus saruna

Oil Settles Week Lower -- Market Talk

2026. g. 13. febr. 19:51 UTC

Peļņas

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

2026. g. 13. febr. 19:32 UTC

Tirgus saruna

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

2026. g. 13. febr. 19:32 UTC

Tirgus saruna

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

2026. g. 13. febr. 19:29 UTC

Peļņas

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

2026. g. 13. febr. 18:18 UTC

Iegādes, apvienošanās, pārņemšana

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

2026. g. 13. febr. 17:52 UTC

Peļņas

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

2026. g. 13. febr. 17:16 UTC

Peļņas

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

2026. g. 13. febr. 17:10 UTC

Iegādes, apvienošanās, pārņemšana

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

2026. g. 13. febr. 16:59 UTC

Peļņas

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

2026. g. 13. febr. 16:39 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

2026. g. 13. febr. 16:11 UTC

Peļņas

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

2026. g. 13. febr. 16:07 UTC

Tirgus saruna

Hungarian Forint Could Rise Further -- Market Talk

2026. g. 13. febr. 15:54 UTC

Peļņas

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

2026. g. 13. febr. 15:26 UTC

Tirgus saruna

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

2026. g. 13. febr. 15:01 UTC

Peļņas

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

2026. g. 13. febr. 15:00 UTC

Peļņas

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

2026. g. 13. febr. 14:50 UTC

Tirgus saruna

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

2026. g. 13. febr. 14:44 UTC

Peļņas

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

2026. g. 13. febr. 14:22 UTC

Tirgus saruna

Peļņas

Global Energy Roundup: Market Talk

2026. g. 13. febr. 14:21 UTC

Tirgus saruna

Peļņas

TC Energy's Broadly Anticipated Results Expected To Have Neutral Response -- Market Talk

2026. g. 13. febr. 14:13 UTC

Tirgus saruna

U.S. Natural Gas Futures Move Lower -- Market Talk

Salīdzinājums

Cenas izmaiņa

Vivani Medical Prognoze

Cenas mērķis

By TipRanks

241.88% augšup

Prognoze 12 mēnešiem

Vidējais 4 USD 241.88%

Augstākais 4 USD

Zemākais 4 USD

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Vivani Medical — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

1 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 1 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Vivani Medical — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Par Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.